In a series of videos, our leading oncology experts discuss EGFR-TKI treatment strategies in patients with EGFR mutation-positive advanced non small cell lung cancer (EGFRm+ NSCLC). Watch our experts share the clinical evidence for 2nd generation EGFR-TKI, Afatinib, and the evidence for sequential therapy in EGFRm+ NSCLC. Learn more about the real world evidence of Afatinib dose modification and adverse event management strategies.
FEATURED VIDEOS
Care for the Skin: EGFR TKI-related Dermatological Adverse Events
Watch A/Prof. Lee take us through the timeline of dermatological AEs associated with EGFR-TKIs as well as the pathophysiological mechanisms underpinning them. Learn how to distinguish between the various cutaneous AEs and the evidence-based treatments for them.
Speaker: Assoc Prof Lee Haur Yueh Document ID: PC-MY-101366
Promoting Ideas and Solutions, in order to Push Improvements in pRecesion Medicine - INSPIRE aims to share the latest updates and perspectives regarding non-small cell lung cancer. Hear from various leading experts all over the world on the current developments in lung cancer and its management.
